C. Lucioni, S. Iannazzo, S. Mazzi, G. Saporiti, S. Chiroli
{"title":"波纳替尼治疗意大利慢性髓性白血病的成本-效果","authors":"C. Lucioni, S. Iannazzo, S. Mazzi, G. Saporiti, S. Chiroli","doi":"10.5301/GRHTA.5000189","DOIUrl":null,"url":null,"abstract":"An area-under-the-curve Markov model was designed to evaluate the cost-effectiveness of ponatinib as a third line treatment of Chronic Myeloid Leukemia-Chronic Phase (CML-CP) with reference to Italy. As for current guidelines, comparators were dasatinib, nilotinib, bosutinib, allogeneic stem cell transplantation (SCT), hydroxyurea. The economic perspective was the Italian National Health Service's (NHS), where costs for treatment drugs, monitoring and follow-up, adverse events, SCT procedure were considered on a lifetime span. Costs (mainly based on current tariffs in Italy) and benefits (QALYs) were discounted at a 3.5% annual rate. Ponatinib resulted dominant versus SCT. The lowest ICER was €13,090 (ponatinib vs hydroxyurea); the highest was €22,529 (ponatinib vs dasatinib). Sensitivity analysis – both deterministic (one way) and probabilistic – was focused on the comparison between ponatinib and dasatinib. The deterministic analysis showed that the most critical parameter in the model was ponatinib pri...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"188 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy\",\"authors\":\"C. Lucioni, S. Iannazzo, S. Mazzi, G. Saporiti, S. Chiroli\",\"doi\":\"10.5301/GRHTA.5000189\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"An area-under-the-curve Markov model was designed to evaluate the cost-effectiveness of ponatinib as a third line treatment of Chronic Myeloid Leukemia-Chronic Phase (CML-CP) with reference to Italy. As for current guidelines, comparators were dasatinib, nilotinib, bosutinib, allogeneic stem cell transplantation (SCT), hydroxyurea. The economic perspective was the Italian National Health Service's (NHS), where costs for treatment drugs, monitoring and follow-up, adverse events, SCT procedure were considered on a lifetime span. Costs (mainly based on current tariffs in Italy) and benefits (QALYs) were discounted at a 3.5% annual rate. Ponatinib resulted dominant versus SCT. The lowest ICER was €13,090 (ponatinib vs hydroxyurea); the highest was €22,529 (ponatinib vs dasatinib). Sensitivity analysis – both deterministic (one way) and probabilistic – was focused on the comparison between ponatinib and dasatinib. The deterministic analysis showed that the most critical parameter in the model was ponatinib pri...\",\"PeriodicalId\":228031,\"journal\":{\"name\":\"Global and Regional Health Technology Assessment\",\"volume\":\"188 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global and Regional Health Technology Assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5301/GRHTA.5000189\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global and Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5301/GRHTA.5000189","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
摘要
参考意大利,设计曲线下面积Markov模型来评估ponatinib作为慢性髓系白血病-慢行期(CML-CP)三线治疗的成本-效果。就目前的指南而言,比较物是达沙替尼、尼洛替尼、博舒替尼、同种异体干细胞移植(SCT)、羟基脲。经济角度是意大利国家卫生服务(NHS),治疗药物、监测和随访、不良事件、SCT手术的费用是在一生中考虑的。成本(主要基于意大利当前的关税)和收益(QALYs)以3.5%的年折现率计算。Ponatinib对SCT结果为优势。最低的ICER为13,090欧元(ponatinib vs羟基脲);最高的是22529欧元(ponatinib vs dasatinib)。敏感性分析-确定性(单向)和概率-集中于波纳替尼和达沙替尼之间的比较。确定性分析表明,模型中最关键的参数是ponatinib pri。
Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy
An area-under-the-curve Markov model was designed to evaluate the cost-effectiveness of ponatinib as a third line treatment of Chronic Myeloid Leukemia-Chronic Phase (CML-CP) with reference to Italy. As for current guidelines, comparators were dasatinib, nilotinib, bosutinib, allogeneic stem cell transplantation (SCT), hydroxyurea. The economic perspective was the Italian National Health Service's (NHS), where costs for treatment drugs, monitoring and follow-up, adverse events, SCT procedure were considered on a lifetime span. Costs (mainly based on current tariffs in Italy) and benefits (QALYs) were discounted at a 3.5% annual rate. Ponatinib resulted dominant versus SCT. The lowest ICER was €13,090 (ponatinib vs hydroxyurea); the highest was €22,529 (ponatinib vs dasatinib). Sensitivity analysis – both deterministic (one way) and probabilistic – was focused on the comparison between ponatinib and dasatinib. The deterministic analysis showed that the most critical parameter in the model was ponatinib pri...